Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

Figure 2

Association between anti-drug antibody status and clinical activity (Ankylosing Spondylitis Disease Activity Score) after switching. Clinical activity classified into inactive (light shading), moderate (medium shading) and high/very high activity (dark shading), according to Ankylosing Spondylitis Disease Activity Score criteria, 6 months after switching to a second anti-TNF drug in patients who had developed anti-drug antibodies (ADA) against the first anti-TNF drug.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us